Effect of Unani drugs in pelvic infectio
- Conditions
- Health Condition 1: N74- Female pelvic inflammatory disorders in diseases classified elsewhereHealth Condition 2: null- Pelvic Inflammatory Disease
- Registration Number
- CTRI/2018/03/012375
- Lead Sponsor
- ational Institue of Unani mediicne
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 66
1. Married women aged from 18-45 years.
2. Women diagnosed with clinical features of waram al-rahim (adnexal and cervical motion tenderness, pelvic discomfort, lower abdominal pain, abnormal vaginal discharge, low backache, dyspareunia, dysuria)1 and other clinical features of uPID (mild/subclinical PID).
1. Pregnant or lactating or had complicated PID (pelvic or tubo-ovarian abscess) and/or any condition likely to require surgical intervention within 24 hours of the start of treatment.
2. Systemic antibacterial therapy <7 days before enrolment
3. History of cardiovascular abnormalities, epilepsy, impaired liver and renal function
4. A history of uterine or pelvic or abdominal surgery <=30 days before treatment5
5. Intolerance to or inability to follow an oral antibiotic regimen
6. Delivery and abortion within last three months.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome: Change in McCormack pain scale and VAS pain scale.Timepoint: Pretest and posttest
- Secondary Outcome Measures
Name Time Method Secondary outcome: Change in health related quality of life assessed by SF-12. <br/ ><br>Timepoint: At baseline (Zero day) and post test on 15th day